Organon & Co. OGN Stock Forecast
AI-powered price prediction and analysis for Organon & Co. · Alpha · vs marketSwitch to Total
See OGN's Exact Price Target · Create a free account and follow this stock to unlock its full AI forecast — 3 stocks free.
Price Chart
Key Statistics
About Organon & Co.
Organon & Co. (OGN) operates within the Life Sciences sector, specifically in the Pharmaceutical Preparations industry.
Latest News
Where OGN sits on the market map
Pharmaceutical Preparations Peers
Companies sharing the same SEC industry code, one row per issuer, largest first - a classification match, not a curated list of competitors.
| Company | AI Signal | Market Cap | P/E |
|---|---|---|---|
| OGN Organon & Co. | ▼ | $3.62B | – |
| LLY Eli Lilly & Co | ▲ | $1.10T | 41.1x |
| JNJ Johnson & Johnson | ▼ | $599.12B | 28.5x |
| ONC Beone Medicines Ltd. | ▶ | $515.98B | – |
| ABBV Abbvie Inc. | ▼ | $484.83B | 76.8x |
| MRK Merck & Co., Inc. | ▼ | $350.29B | 110.4x |
| NVS Novartis Ag | ▼ | $271.74B | – |
| GSK Gsk Plc | ▼ | $199.68B | – |
| ABT Abbott Laboratories | ▶ | $178.73B | 28.6x |
| PFE Pfizer Inc | ▲ | $161.70B | 37.3x |
| VRTX Vertex Pharmaceuticals Inc / … | ▼ | $122.98B | 27.9x |
| BMY Bristol Myers Squibb Co | ▼ | $115.76B | 12.5x |
| REGN Regeneron Pharmaceuticals, Inc. | ▶ | $77.54B | 17.9x |
| TEVA Teva Pharmaceutical Industries Ltd | ▶ | $48.07B | 68.0x |
| SNY Sanofi | ▼ | $47.70B | – |
| RPRX Royalty Pharma Plc | ▲ | $32.53B | 39.9x |
| ZTS Zoetis Inc. | ▼ | $30.70B | 11.7x |
| ALNY Alnylam Pharmaceuticals, Inc. | ▼ | $29.95B | – |
| TAK Takeda Pharmaceutical Co Ltd | ▼ | $29.46B | – |
| ATHE Alterity Therapeutics Ltd | ▶ | $26.01B | – |
| ZLAB Zai Lab Ltd | ▼ | $25.93B | – |
| ROIV Roivant Sciences Ltd. | ▶ | $24.09B | – |
| UTHR United Therapeutics Corp | ▼ | $23.31B | 17.8x |
| INSM Insmed Inc | ▶ | $21.14B | – |
| VTRS Viatris Inc | ▶ | $19.81B | – |
| ASND Ascendis Pharma A/S | ▶ | $13.83B | – |
| JAZZ Jazz Pharmaceuticals Plc | ▶ | $13.66B | 14.5x |
| CORT Corcept Therapeutics Inc | ▲ | $12.73B | – |
| SMMT Summit Therapeutics Inc. | ▶ | $12.38B | – |
| BBIO Bridgebio Pharma, Inc. | ▶ | $12.37B | – |
| KNSA Kiniksa Pharmaceuticals International, Plc | ▲ | $12.25B | – |
| HCM Hutchmed (China) Ltd | ▶ | $11.78B | – |
| ELAN Elanco Animal Health Inc | ▶ | $11.20B | – |
| RDY Dr Reddys Laboratories Ltd | ▼ | $10.66B | – |
| BMRN Biomarin Pharmaceutical Inc | ▼ | $10.53B | – |
| MDGL Madrigal Pharmaceuticals, Inc. | ▶ | $10.45B | – |
| PTGX Protagonist Therapeutics, Inc | ▲ | $8.96B | – |
| CYTK Cytokinetics Inc | ▶ | $8.57B | – |
| ARWR Arrowhead Pharmaceuticals, Inc. | ▲ | $8.21B | – |
| AXSM Axsome Therapeutics, Inc. | ▼ | $8.19B | – |
| SYRE Spyre Therapeutics, Inc. | ▲ | $7.09B | – |
| IONS Ionis Pharmaceuticals Inc | ▶ | $7.04B | – |
| PRAX Praxis Precision Medicines, Inc. | ▶ | $6.79B | – |
| ABVX Abivax S.A. | ▼ | $6.77B | – |
| ALKS Alkermes Plc. | ▶ | $6.67B | – |
| LEGN Legend Biotech Corp | ▶ | $6.61B | – |
| AMRX Amneal Pharmaceuticals, Inc. | ▶ | $6.25B | – |
| LGND Ligand Pharmaceuticals Inc | ▼ | $6.05B | 30.7x |
| BLTE Belite Bio, Inc | ▲ | $5.97B | – |
| RYTM Rhythm Pharmaceuticals, Inc. | ▶ | $5.96B | – |
| BLRX Biolinerx Ltd. | ▶ | $5.67B | – |
| MIRM Mirum Pharmaceuticals, Inc. | ▲ | $5.17B | – |
| ERAS Erasca, Inc. | ▲ | $5.17B | – |
| PTCT Ptc Therapeutics, Inc. | ▶ | $5.00B | – |
| TVTX Travere Therapeutics, Inc. | ▲ | $4.88B | – |
| COGT Cogent Biosciences, Inc. | ▼ | $4.87B | – |
| AMRN Amarin Corp Plc\Uk | ▶ | $4.86B | – |
| MANE Veradermics, Inc | ▲ | $4.86B | – |
| GPCR Structure Therapeutics Inc. | ▲ | $4.77B | – |
| DNTH Dianthus Therapeutics, Inc. /De/ | ▲ | $4.34B | – |
FAQ
Is Organon & Co. a good stock to buy?
Our AI analyzes Organon & Co. daily. Check the signal above for the latest recommendation. Always do your own research before investing.
How accurate are Organon & Co. predictions?
A per-ticker accuracy statistic for OGN is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are forecasts updated?
Organon & Co. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Ready to invest smarter? · Join thousands of investors using AI-powered stock predictions
Sign Up FreeLooking for a deeper analysis of Organon & Co.? View full institutional-grade analysis on Intratio →
AI predictions are based on historical patterns and should not be the sole basis for investment decisions. Past performance does not guarantee future results. Always do your own research.